Hedley Ca Emsley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7242810/publications.pdf

Version: 2024-02-01

201674 144013 3,539 64 27 57 citations h-index g-index papers 69 69 69 5108 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology, 2004, 4, 2.	1.8	389
2	Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurology, The, 2008, 7, 341-353.	10.2	370
3	An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. Journal of Neuroimmunology, 2003, 139, 93-101.	2.3	264
4	Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke, 2005, 36, 1316-1329.	2.0	256
5	HIV infection and stroke: current perspectives and future directions. Lancet Neurology, The, 2012, 11, 878-890.	10.2	231
6	Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurology, The, 2018, 17, 539-547.	10.2	192
7	Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurology, The, 2019, 18, 653-665.	10.2	143
8	HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults. Neurology, 2016, 86, 324-333.	1.1	129
9	The incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virology Journal, 2008, 5, 134.	3.4	118
10	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1375-1386.	13.7	104
11	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1363-1374.	13.7	93
12	Inflammation in Acute Ischemic Stroke and its Relevance to Stroke Critical Care. Neurocritical Care, 2008, 9, 125-138.	2.4	87
13	Calibrated fMRI during a cognitive Stroop task reveals reduced metabolic response with increasing age. Neurolmage, 2012, 59, 1143-1151.	4.2	73
14	Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurology, 2007, 7, 5.	1.8	70
15	Variability of the systemic acute phase response after ischemic stroke. Journal of the Neurological Sciences, 2006, 251, 77-81.	0.6	62
16	Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease. Neurolmage: Clinical, 2014 , 6 , 1 - 8 .	2.7	62
17	Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine, 2012, 58, 384-389.	3.2	57
18	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. Movement Disorders, 2021, 36, 2583-2594.	3.9	54

#	Article	IF	CITATIONS
19	Prevalence and subtypes of radiological cerebrovascular disease in late-onset isolated seizures and epilepsy. Clinical Neurology and Neurosurgery, 2013, 115, 591-596.	1.4	50
20	Structural and physiological neurovascular changes in idiopathic Parkinson's disease and its clinical phenotypes. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3409-3421.	4.3	50
21	Arterial ischemic stroke in HIV. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e254.	6.0	45
22	Late-Onset Epilepsy and Occult Cerebrovascular Disease. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 564-570.	4.3	42
23	Cognitive Impairment Before Intracerebral Hemorrhage Is Associated With Cerebral Amyloid Angiopathy. Stroke, 2018, 49, 40-45.	2.0	39
24	Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis. Lancet Neurology, The, 2019, 18, 666-673.	10.2	39
25	Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurology, The, 2021, 20, 294-303.	10.2	37
26	Hi4D-ADSIP 3-D dynamic facial articulation database. Image and Vision Computing, 2012, 30, 713-727.	4.5	36
27	Inflammatory demyelinating polyradiculoneuropathy associated with membranous glomerulonephritis and thrombocytopaenia. Clinical Neurology and Neurosurgery, 2002, 105, 23-26.	1.4	33
28	The challenges of implementing a telestroke network: a systematic review and case study. BMC Medical Informatics and Decision Making, 2013, 13, 125.	3.0	26
29	Structural and physiological MRI correlates of occult cerebrovascular disease in late-onset epilepsy. NeuroImage: Clinical, 2015, 9, 128-133.	2.7	26
30	Prevalence of radiological and clinical cerebrovascular disease in idiopathic Parkinson's disease. Clinical Neurology and Neurosurgery, 2011, 113, 830-834.	1.4	25
31	Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 14-30.	4.3	25
32	The Oxfordshire Community Stroke Project classification in the early hours of ischemic stroke and relation to infarct site and size on cranial computed tomography. Journal of Stroke and Cerebrovascular Diseases, 2001, 10, 205-209.	1.6	24
33	Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported. Health Information Management Journal, 2020, 49, 58-61.	1.2	24
34	GLP-1 receptor agonists for Parkinson's disease. The Cochrane Library, 2020, 2020, CD012990.	2.8	24
35	Dermatomes and dogma. Practical Neurology, 2011, 11, 100-105.	1.1	18
36	<i>àê⁻It was like he was in the room with us':</i> patients' and carers' perspectives of telemedicine in acute stroke. Health Expectations, 2016, 19, 98-111.	2.6	17

#	Article	IF	CITATIONS
37	Variations in inflammation-related genes may be associated with childhood febrile seizure susceptibility. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 457-461.	2.0	16
38	The impact of smoking cessation on multiple sclerosis disease progression. Brain, 2022, 145, 1368-1378.	7.6	16
39	Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol. European Stroke Journal, 2021, 6, 89-101.	5.5	15
40	Rapidly progressive polyneuropathy due to dry beriberi in a man: a case report. Journal of Medical Case Reports, 2010, 4, 409.	0.8	14
41	Infection and Brain-Induced Immunodepression After Acute Ischemic Stroke. Stroke, 2008, 39, e7; author reply e8.	2.0	11
42	Seizures in the context of occult cerebrovascular disease. Epilepsy and Behavior, 2020, 104, 106396.	1.7	11
43	Reliability of a Semi-Automated Technique of Cerebral Infarct Volume Measurement with CT. Cerebrovascular Diseases, 2004, 18, 220-226.	1.7	10
44	Myasthenia gravis as a â€~stroke mimic' – it's all in the history. Clinical Medicine, 2014, 14, 640-642.	1.9	10
45	Late-onset epilepsy predicts stroke: Systematic review and meta-analysis. Epilepsy and Behavior, 2021, 115, 107634.	1.7	10
46	Correlation of Systemic Inflammatory Response With Infarct Volume in Acute Ischemic Stroke Patients. Stroke, 2005, 36, 228-229.	2.0	9
47	Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: observational study. Trials, 2017, 18, 162.	1.6	9
48	Illicit Drugs and Reversible Cerebral Vasoconstriction Syndrome. Neurohospitalist, The, 2021, 11, 40-44.	0.8	8
49	Interleukin-6 and acute ischaemic stroke. Acta Neurologica Scandinavica, 2005, 112, 273-274.	2.1	6
50	Routinely collected patient data in neurology research: a systematic mapping review. BMC Neurology, 2020, 20, 431.	1.8	6
51	Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Research, 2019, 8, 1039.	1.6	6
52	Baseline factors associated with early and late death in intracerebral haemorrhage survivors. European Journal of Neurology, 2020, 27, 1257-1263.	3.3	5
53	Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Research, 2019, 8, 1039.	1.6	5
54	When stopping the antiplatelet drugs stopped the †TIAs'. Practical Neurology, 2012, 12, 36-39.	1.1	4

#	Article	IF	CITATIONS
55	GLP-1 receptor agonists for Parkinson's disease. The Cochrane Library, 0, , .	2.8	4
56	Extracranial arterial wall volume is increased and shows relationships with vascular MRI measures in idiopathic Parkinson's disease. Clinical Neurology and Neurosurgery, 2018, 167, 54-58.	1.4	3
57	Improving undergraduate clinical neurology bedside teaching: opening the magic circle. Clinical Teacher, 2009, 6, 172-176.	0.8	1
58	Elevated Circulating Interleukin-6 Levels in Acute Ischaemic Stroke Are Correlated with Ct Infarct Volume and Poor Clinical Outcome. Clinical Science, 2002, 103, 18P-19P.	0.0	0
59	Circle of Willis variation in a complex stroke presentation: a case report. BMC Neurology, 2006, 6, 13.	1.8	0
60	WHITE MATTER LESIONS AFTER CEREBRAL ANEURYSM COILING. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.121-e4.	1.9	0
61	SIMILARITIES IN ARTERIAL ARRIVAL TIME PROLONGATION AND POSTERIOR HYPOPERFUSION IN PATIENTS WITH IDIOPATHIC PARKINSON'S DISEASE AND STROKE. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.78-e4.	1.9	0
62	Response. Clinical Medicine, 2015, 15, 212.	1.9	0
63	Acute Stroke Training and Assessment in Computerised Axial Tomography (ASTRACAT) for stroke physicians: facilitating telestroke implementation in a UK setting. Journal of Contemporary Medical Education, 2013, 1, 137.	0.2	0
64	Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2022, 2022, .	2.8	0